Display options
Cite
Stroes CI, Schokker S, Molenaar RJ, et al. A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers (Basel). 2021;13(4)doi: 10.3390/cancers13040839.
Stroes, C. I., Schokker, S., Molenaar, R. J., Mathôt, R. A. A., Bijlsma, M. F., van der Woude, S. O., Belo Pereira, J. P., Hooijer, G. K. J., Verhoeven, R. H. A., Cats, A., Grootscholten, C., van Sandick, J. W., Creemers, G. J., Nieuwenhuijzen, G. A. P., Haj Mohammad, N., Ruurda, J. P., Meijer, S. L., Hulshof, M. C. C. M., van Berge Henegouwen, M. I., & van Laarhoven, H. W. M. (2021). A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers, 13(4), . https://doi.org/10.3390/cancers13040839
Stroes, Charlotte I, et al. "A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX." Cancers vol. 13,4 (2021). doi: https://doi.org/10.3390/cancers13040839
Stroes CI, Schokker S, Molenaar RJ, Mathôt RAA, Bijlsma MF, van der Woude SO, Belo Pereira JP, Hooijer GKJ, Verhoeven RHA, Cats A, Grootscholten C, van Sandick JW, Creemers GJ, Nieuwenhuijzen GAP, Haj Mohammad N, Ruurda JP, Meijer SL, Hulshof MCCM, van Berge Henegouwen MI, van Laarhoven HWM. A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers (Basel). 2021 Feb 17;13(4). doi: 10.3390/cancers13040839. PMID: 33671266; PMCID: PMC7922275.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Feb 17;13(4). doi: 10.3390/cancers13040839.

A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX.

Cancers

Charlotte I Stroes, Sandor Schokker, Remco J Molenaar, Ron A A Mathôt, Maarten F Bijlsma, Stephanie O van der Woude, João P Belo Pereira, Gerrit K J Hooijer, Rob H A Verhoeven, Annemieke Cats, Cecile Grootscholten, Johanna W van Sandick, Geert-Jan Creemers, Grard A P Nieuwenhuijzen, Nadia Haj Mohammad, Jelle P Ruurda, Sybren L Meijer, Maarten C C M Hulshof, Mark I van Berge Henegouwen, Hanneke W M van Laarhoven

Affiliations

  1. Cancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  2. Center for Experimental and Molecular Medicine (CEMM), Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology (LEXOR), Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  3. Department of Hospital Pharmacy and Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  4. Oncode Institute, 3521 AL Utrecht, The Netherlands.
  5. Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  6. Department of Pathology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  7. Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), 3511 DT Utrecht, The Netherlands.
  8. The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Department of Gastrointestinal Oncology, 1066 CX Amsterdam, The Netherlands.
  9. Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
  10. Department of Medical Oncology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands.
  11. Department of Surgery, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands.
  12. University Medical Center Utrecht, Department of Clinical Oncology, Utrecht University, 3584 CX Utrecht, The Netherlands.
  13. University Medical Center Utrecht, Department of Surgery, 3584 CX Utrecht, The Netherlands.
  14. Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  15. Department of Surgery, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

PMID: 33671266 PMCID: PMC7922275 DOI: 10.3390/cancers13040839

Abstract

We assessed the feasibility of adjuvant S-1 and oxaliplatin following neoadjuvant chemoradiotherapy (nCRT) and esophagectomy. Patients treated with nCRT (paclitaxel, carboplatin) and esophagectomy received six 21-day cycles with oxaliplatin (130 mg/m

Keywords: S-1; S-1 pharmacokinetics; adjuvant chemotherapy; esophageal adenocarcinoma; oxaliplatin; predictive biomarkers; proteomics

References

  1. J Clin Oncol. 2000 Jul;18(14):2772-9 - PubMed
  2. Cancer Chemother Pharmacol. 2013 Jul;72(1):159-65 - PubMed
  3. Anticancer Drugs. 2006 Apr;17(4):393-9 - PubMed
  4. Ann Thorac Surg. 2016 Jan;101(1):200-8; discussion 208-10 - PubMed
  5. J Clin Pathol. 2006 Mar;59(3):260-3 - PubMed
  6. Clin Cancer Res. 2005 Jul 1;11(13):4810-7 - PubMed
  7. J Clin Oncol. 2007 Jan 1;25(1):102-9 - PubMed
  8. Ann Surg. 2017 Aug;266(2):297-304 - PubMed
  9. N Engl J Med. 2006 Jul 6;355(1):11-20 - PubMed
  10. Ann Oncol. 2017 Jun 1;28(6):1288-1293 - PubMed
  11. N Engl J Med. 2012 May 31;366(22):2074-84 - PubMed
  12. Eur J Surg Oncol. 2015 Oct;41(10):1300-7 - PubMed
  13. Clin Cancer Res. 2003 Jan;9(1):134-42 - PubMed
  14. Ann Thorac Surg. 2019 Sep;108(3):828-836 - PubMed
  15. Ann Oncol. 2010 May;21(5):1001-5 - PubMed
  16. Br J Cancer. 2018 Feb 6;118(3):331-337 - PubMed
  17. Lung Cancer. 2008 Jun;60(3):401-7 - PubMed
  18. J Clin Oncol. 2009 Oct 20;27(30):5062-7 - PubMed
  19. Nature. 2013 Sep 19;501(7467):338-45 - PubMed
  20. Comput Methods Programs Biomed. 2010 Sep;99(3):306-14 - PubMed
  21. Dig Liver Dis. 2018 Oct;50(10):991-996 - PubMed
  22. Cancer Chemother Pharmacol. 2000;46 Suppl:S27-32 - PubMed
  23. Gastric Cancer. 2017 Jan;20(1):175-181 - PubMed
  24. N Engl J Med. 2007 Nov 1;357(18):1810-20 - PubMed
  25. EMBO Rep. 2020 May 6;21(5):e48780 - PubMed
  26. JAMA Oncol. 2020 Apr 1;6(4):547-551 - PubMed
  27. CPT Pharmacometrics Syst Pharmacol. 2019 Dec;8(12):940-950 - PubMed
  28. Ann Surg Oncol. 2011 Sep;18(9):2442-52 - PubMed
  29. Cancer Chemother Pharmacol. 2007 Oct;60(5):693-701 - PubMed
  30. Neuro Oncol. 2016 Jun;18(6):797-806 - PubMed
  31. J Clin Oncol. 2011 May 1;29(13):1715-21 - PubMed
  32. Drug Metab Dispos. 2014 Sep;42(9):1485-92 - PubMed
  33. J Thorac Oncol. 2012 Jun;7(6):982-92 - PubMed
  34. Ann Surg. 2008 Feb;247(2):365-71 - PubMed
  35. Ann Oncol. 2015 Jan;26(1):141-148 - PubMed
  36. Xenobiotica. 1996 Apr;26(4):395-403 - PubMed
  37. Eur J Cancer. 2012 Mar;48(4):518-26 - PubMed
  38. Br J Cancer. 2013 Oct 15;109(8):2096-105 - PubMed
  39. Lancet Oncol. 2012 Nov;13(11):1125-32 - PubMed
  40. J Clin Pharmacol. 2015 Aug;55(8):926-35 - PubMed
  41. Lancet. 2012 Jan 28;379(9813):315-21 - PubMed
  42. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  43. Genomics. 1999 Jun 15;58(3):310-2 - PubMed
  44. Cancer Chemother Pharmacol. 2010 Feb;65(3):473-80 - PubMed
  45. Clin Cancer Res. 2017 Mar 15;23(6):1607-1620 - PubMed
  46. Sci Rep. 2018 Sep 5;8(1):13281 - PubMed
  47. J Thorac Cardiovasc Surg. 2010 Feb;139(2):387-94 - PubMed
  48. J Thorac Dis. 2019 Apr;11(Suppl 5):S835-S844 - PubMed
  49. Cancer. 1994 Jun 1;73(11):2680-6 - PubMed

Publication Types